This study was funded with internal resources. The funding source had no involvement in study design and conduct, in the collection, management, analysis, and interpretation of data, in the writing of the report or in the decision to submit the paper for publication. The authors declare that none of them have a conflict of interest.
Reference List
1. Vansteenkiste J, Fischer BM, Dooms C et al: Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5:531-540, 2004. 2. Jemal A, Siegel R, Ward E et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006. 3. Kopp R, Weidenhagen R, Reinmiedl J et al: Outcome following lung resections for pT1 non-small
cell lung cancer. Eur J Surg Oncol 32:329-334, 2006.
4. Vokes E: Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer 50 Suppl 1:S20-S22, 2005.
5. Endo S, Tsubochi H, Tetsuka K et al: Preoperative chemotherapy for cStage III-pN0 patients with non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 54:109-113, 2006.
6. Rigas JR, Lara PN, Jr.: Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer 50 Suppl 2:S17-S24, 2005.
7. Furuse K, Fukuoka M, Kawahara M et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699, 1999.
8. Arriagada R, Bergman B, Dunant A et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
9. Winton T, Livingston R, Johnson D et al: Vinorelbine plus cisplatin vs. observation in resected non- small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
10. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997.
11. van Rens MT, de la Riviere AB, Elbers HR et al: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117:374- 379, 2000.
12. Watanabe Y: TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 9:343-350, 2003. 13. Jones DR, Daniel TM, Denlinger CE et al: Stage IB Nonsmall Cell Lung Cancers: Are They All the
Same? Ann Thorac Surg 81:1958-1962, 2006.
14. Verhagen AF, Bootsma GP, Tjan-Heijnen VC et al: FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 44:175-181, 2004.
15. van Tinteren H, Hoekstra OS, Smit EF et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388-1393, 2002.
16. Pieterman RM, van Putten JW, Meuzelaar JJ et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000.
17. Vesselle H, Turcotte E, Wiens L et al: Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis. Clin Cancer Res 10:4709-4716, 2004.
18. Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507, 2006.
19. Younes M, Brown RW, Stephenson M et al: Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051, 1997.
20. Kunkel M, Reichert TE, Benz P et al: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015-1024, 2003.
21. Smith TA: FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 19:97-105, 1998.
22. Akhurst T, Kates TJ, Mazumdar M et al: Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23:8713-8716, 2005.
23. Duhaylongsod FG, Lowe VJ, Patz EF, Jr. et al: Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60:1348-1352, 1995.
24. Vesselle H, Schmidt RA, Pugsley JM et al: Lung cancer proliferation correlates with [F- 18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6:3837-3844, 2000.
25. Arai T, Kuroishi T, Saito Y et al: Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 24:199-204, 1994.
26. Usuda K, Saito Y, Sagawa M et al: Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239-2244, 1994.
27. Tirindelli-Danesi D, Teodori L, Mauro F et al: Prognostic significance of flow cytometry in lung cancer. A 5-year study. Cancer 60:844-851, 1987.
28. Gallego MA, Joseph B, Hemstrom TH et al: Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 23:6282-6291, 2004.
29. Sasaki R, Komaki R, Macapinlac H et al: [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23:1136-1143, 2005. 30. Takata T, Tanaka F, Yamada T et al: Clinical significance of caspase-3 expression in pathologic-stage
31. Clavo AC, Brown RS, Wahl RL: Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625-1632, 1995.
32. Mamede M, Higashi T, Kitaichi M et al: [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 7:369-379, 2005.
33. Lee JD, Yang WI, Park YN et al: Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 46:1753-1759, 2005.
34. Pan CC, Chen PC, Chiang H: An easy method for manual construction of high-density tissue arrays. Appl Immunohistochem Mol Morphol 12:370-372, 2004.
35. Higashi K, Ueda Y, Sakurai A et al: Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 27:1778-1785, 2000.
36. Marom EM, Aloia TA, Moore MB et al: Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33:99-107, 2001.
37. Chung JK, Lee YJ, Kim SK et al: Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25:11-17, 2004.
38. Brown RS, Leung JY, Kison PV et al: Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40:556-565, 1999.
39. Chung JH, Cho KJ, Lee SS et al: Overexpression of Glut1 in lymphoid follicles correlates with false- positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 45:999-1003, 2004.
40. Eschmann SM, Friedel G, Paulsen F et al: Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33:263- 269, 2006.
41. Ahuja V, Coleman RE, Herndon J et al: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 83:918-924, 1998.
42. Downey RJ, Akhurst T, Gonen M et al: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255-3260, 2004.
43. Dhital K, Saunders CA, Seed PT et al: [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 18:425-428, 2000.
44. Vansteenkiste JF, Stroobants SG, Dupont PJ et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small- cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999.
45. Jeong HJ, Min JJ, Park JM et al: Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23:865-870, 2002.
46. Higashi K, Ueda Y, Arisaka Y et al: 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39-45, 2002.
47. Yasuda S, Arii S, Mori A et al: Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40:117-123, 2004.
48. Haberkorn U, Bellemann ME, Brix G et al: Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 28:418-425, 2001.
49. Ishikawa N, Oguri T, Isobe T et al: SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 92:874-879, 2001.
Radiology 237:181-188, 2005